Noom Med
US$ 23.23
retatrutide ly3437943 triple agonist gip glp-1 glucagon LY3437943, a novel glucagon, GIP, and receptor for glycemic control and weight loss: From discovery to clinical proof of concept Retatrutide Guide 2023: Weight Loss,
Description
Get a personalized plan, provider review, and ongoing supportall with a simple online process.
95% CI 0.97, 1.15)
NPR Pharmaceuticals Correspondent Sydney Lupkin chats about these experimental pills with host Emily Kwong.Check out more of NPRs coverage about GLP-1s.Interested in more health stories
GLP-1 receptor agonists got their start in an unlikely place: the mouth of a lizard
Gastric ultrasound identifies increased residual gastric contents in patients on GLP-1 receptor agonists, showing that shorter drug withholding and fasting times are linked to higher aspiration risk before anesthesia.
